Agenus Inc. Terminates Material Definitive Agreement
Ticker: AGEN · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1098972
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Agenus Inc. just terminated a major deal. Big changes coming?
AI Summary
Agenus Inc. reported on February 4, 2025, the termination of a material definitive agreement. The company, formerly known as Antigenics Inc. /DE/, is incorporated in Delaware and headquartered in Lexington, Massachusetts.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals significant business changes or challenges that could affect the company's performance.
Key Players & Entities
- Agenus Inc. (company) — Registrant
- Antigenics Inc. /DE/ (company) — Former Company Name
- February 04, 2025 (date) — Date of earliest event reported
- February 10, 2025 (date) — Filing Date
- Lexington, Massachusetts (location) — Principal Executive Offices
FAQ
What was the specific material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not specify which agreement it was.
When did the termination of the agreement become effective?
The filing reports the date of the earliest event as February 04, 2025, which is likely the effective date of the termination.
What are the potential consequences of this termination for Agenus Inc.?
The filing does not detail the potential consequences, but the termination of a material agreement typically has significant business implications.
Was there any financial impact associated with this termination?
The filing does not provide specific financial details regarding the termination.
Does Agenus Inc. have any other material agreements that are at risk?
This filing only addresses the termination of one specific material definitive agreement and does not provide information on other agreements.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2025-02-10 16:05:08
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
Filing Documents
- agen-20250204.htm (8-K) — 40KB
- 0000950170-25-017028.txt ( ) — 147KB
- agen-20250204.xsd (EX-101.SCH) — 23KB
- agen-20250204_htm.xml (XML) — 4KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. In January 2015, Agenus Inc. (the "Company") entered into a License, Development, and Commercialization Agreement (the "Agreement") with Incyte Corporation ("Incyte"), under which Incyte licensed exclusive rights to certain immuno-oncology programs, including antibodies targeting GITR, OX40, TIM-3, LAG-3, and additional undisclosed targets. Incyte previously terminated the OX40 program (effective October 2023) and the GITR and an undisclosed program (effective May 2024). In July 2024, Incyte announced that it would discontinue development of its LAG-3 and TIM-3 programs. On February 4, 2025, Agenus received formal notice from Incyte electing to terminate the Agreement effective February 4, 2026, in line with its strategic portfolio reprioritization. Upon termination, all rights to LAG-3 and TIM-3 revert to Agenus. With this termination, Agenus will regain full control of these assets and will evaluate future opportunities for their advancement, including internal development and potential new partnerships. The foregoing summary of the material terms of the Agreement is qualified in its entirety by the complete terms and conditions of the Agreement, filed with the Securities and Exchange Commission on March 16, 2015, as Exhibit 10.22 to the Company's Annual Report on Form 10-K for the year ended December 31, 2014 and the First Amendment to the Agreement filed on May 4, 2017, as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 10, 2025 By: /s/ Christine M. Klaskin Christine M. Klaskin, VP Finance